Keros Therapeutics Announces $20M Milestone Payment from Takeda

What Happened

• On July 30, 2026, Keros Therapeutics, Inc. announced it will receive a $20 million development milestone payment from partner Takeda Pharmaceuticals U.S.A., Inc. The payment is triggered by the dosing of the first patient in ELRiSE MDS, a Phase 3, multicenter, open‑label, randomized trial comparing elritercept versus epoetin alfa for anemia in very low, low, or intermediate‑risk myelodysplastic syndromes (MDS). The company furnished a press release as Exhibit 99.1 to the Form 8-K.

Key Details

• $20 million development milestone payment to Keros from Takeda.
• Trigger event: dosing of the first patient in the ELRiSE MDS Phase 3 trial.
• Trial compares elritercept to epoetin alfa for anemia in very low/low/intermediate‑risk MDS.
• Announcement dated July 30, 2026; press release furnished as Exhibit 99.1 (information furnished, not “filed,” under the Exchange Act).

Why It Matters

• This milestone represents a material, near‑term cash inflow tied to clinical progress for elritercept and confirms advancement of the Phase 3 ELRiSE MDS program with Takeda.
• For investors, the payment is a concrete sign of development progress and a potential boost to Keros’s near‑term financial resources; it also reflects partner validation of the program moving into a pivotal trial.